LayerBio has been awarded a $1.2 million small business grant from the National Eye Institute in order to develop a sustained-release travoprost formulation for the treatment of glaucoma, according to a press release.
The formulation is based on LayerBio’s PolyNet platform, a network polymer-based drug delivery technology, the release said.
“Sustained-release formulations offer an important alternative to eye drops because they provide around-the-clock coverage for patients suffering [from] glaucoma,” Ken Mandell, MD, PhD, founder and CEO of LayerBio, said in the release. “They
Uncategorized